Research field (4):
Healthcare management, medical sociology
, Web and service informatics
, Biological, health, and medical informatics
, Clinical psychology
Research theme for competitive and other funds (5):
2022 - 2024 N/A
2017 - 2022 Acute and medium- to long-term effects of Asian dust and air pollutants on allergies and biomarker search
2019 - 2022 Research on inter-institutional collaboration for promoting use of CDISC standard in academia
2015 - 2019 アカデミアにおける臨床研究データ管理のCDISC準拠体制モデルの構築
ラミニンγ2単鎖測定による高悪性度膵がん診断、治療効果予測の前向き研究
Papers (15):
Takehiko Okamura, Kouji Izumi, Satoshi Kurokawa, Takashi Shima, Yuki Kato, Koji Mita, Manabu Kamiyama, Shogo Inoue, Seiji Hoshi, Nobumichi Tanaka, et al. Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study. The Prostate. 2025
Nobumichi Tanaka, Kouji Izumi, Yasushi Nakai, Takashi Shima, Yuki Kato, Koji Mita, Manabu Kamiyama, Shogo Inoue, Seiji Hoshi, Takehiko Okamura, et al. Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa. The Prostate. 2024
Anri Inaki, Atsushi Mizokami, Hiroshi Wakabayashi, Kouji Izumi, Yoshifumi Kadono, Tadashi Toyama, Shizuko Takahara, Toshinori Murayama, Seigo Kinuya. Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer. Annals of Nuclear Medicine. 2024. 38. 8. 587-595
Yoshifumi Kadono, Hiroyuki Konaka, Takahiro Nohara, Kouji Izumi, Satoshi Anai, Kiyohide Fujimoto, Tomoyuki Koguchi, Kei Ishibashi, Noriyasu Kawai, Keita Nakane, et al. Efficacy and Safety of First-Line Cytokines Versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Cancers. 2023. 15. 10. 2745-2759
Shizuko Takahara, Nanayo Aoki, Kenkei Hasatani, Yasuhito Imai, Toshinori Murayama. A model of a hybrid system for randomization on that day. Japanese Pharmacology and Therapeutics. 2017. 45
Examination of 42 Cases of Blunders in CDISC/SDTM in Physician-led/Industry-led Clinical Trials: Insights from the Field
(2024 CDISC Japan Interchange 2024)